Cat. No.: HY-N0264

Ligustrazine

(Synonyms: Chuanxiongzine; Tetramethylpyrazine)

11 Cited Publications

Avis client

Based on 11 publication(s) in Google Scholar

Ligustrazine (Chuanxiongzine) is an orally active, blood-brain barrier-permeable alkaloid. It can be isolated from Ligusticum striatum DC. Ligustrazine reduces ROS, upregulates the levels of p-Akt/Akt and p-eNOS/eNOS, and decreases ALT and AST. It inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume and brain water content. Ligustrazine possesses anti-inflammatory, antioxidant, lipid-lowering, endothelial protective and hepatoprotective activities. It can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury and atherosclerosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.99%
CAS No.: 1124-11-4
Formule: C₈H₁₂N₂
Masse moléculaire:136.20

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ligustrazine Chemical Structure

CAS No.: 1124-11-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (11)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

eNOS

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform NO Synthase :

Voir tous les produits spécifiques à Isoform Aminotransferases (Transaminases) :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>20 μM Compound: Lig	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37499289]
A549	IC₅₀	>200 μM Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26891099]
A549	IC₅₀	>200 μM Compound: 1	Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry	[PMID: 26891099]
A549	IC₅₀	15.22 μM Compound: 2	Antiproliferative activity against human A549 cells after 72 hrs in presence of piperlongumine by MTT assay Antiproliferative activity against human A549 cells after 72 hrs in presence of piperlongumine by MTT assay	[PMID: 29424539]
A549	IC₅₀	36.46 μM Compound: TMP	Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
A549	IC₅₀	6.42 μM Compound: Lig	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay	[PMID: 37499289]
A549/CDDP	IC₅₀	>200 μM Compound: 1	Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay	[PMID: 26891099]
A549/CDDP	IC₅₀	>200 μM Compound: 1	Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry	[PMID: 26891099]
Bel-7402	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 29432947]
EA.hy 926	EC₅₀	83.4 μM Compound: Ligustrazine, TMP	Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay	10.1039/C4MD00022F
ECV-304	EC₅₀	0.6 mM Compound: TMP, Ligustrazine	Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay Cytoprotective activity in H2O2-induced human ECV304 cells assessed as proliferation rate incubated for 24 hrs prior to H2O2-challenge measured after 12 hrs by MTT assay	10.1039/C3MD20352B
ECV-304	EC₅₀	0.6 mM Compound: TMP, tetramethyl pyrazine	Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay Protection against H2O2-induced toxicity in human ECV304 cells assessed as proliferation rate pretreated for 24 hrs before H2O2 challenge measured after 12 hrs by MTT assay	[PMID: 21993151]
ECV-304	EC₅₀	154.35 μM Compound: Lig, Ligustrazine	Protection against hydrogen peroxide-induced cell damage in human ECV304 cells treated 30 mins before hydrogen peroxide challenge measured after 6 hrs Protection against hydrogen peroxide-induced cell damage in human ECV304 cells treated 30 mins before hydrogen peroxide challenge measured after 6 hrs	[PMID: 19329327]
ECV-304	EC₅₀	452 μM Compound: ligustrazine	Protection of hydrogen peroxide-induced damage in ECV304 cells Protection of hydrogen peroxide-induced damage in ECV304 cells	[PMID: 17383884]
ECV-304	EC₅₀	549 μM Compound: Ligustrazine	Protection against H2O2-induced damage in human ECV304 cells preincubated for 24 hrs followed by H2O2 addition and measured after 12 hrs by MTT assay Protection against H2O2-induced damage in human ECV304 cells preincubated for 24 hrs followed by H2O2 addition and measured after 12 hrs by MTT assay	[PMID: 29432947]
HBMEC-2	EC₅₀	15.18 μM Compound: TMP	Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay	[PMID: 31541868]
HCT-116	IC₅₀	8.17 μM Compound: 2	Antiproliferative activity against human HCT116 cells after 72 hrs in presence of piperlongumine by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs in presence of piperlongumine by MTT assay	[PMID: 29424539]
HeLa	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29432947]
HepG2	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29432947]
HepG2	IC₅₀	38.25 μM Compound: TMP	Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
HT-29	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29432947]
HUVEC	EC₅₀	600 μM Compound: Ligustrazine	Protection against H2O2-induced damage in HUVEC Protection against H2O2-induced damage in HUVEC	[PMID: 29432947]
HUVEC	EC₅₀	788 μM Compound: Ligustrazine	Protection against H2O2-induced damage in HUVEC preincubated for 0.5 hrs followed by H2O2 addition and measured after 12 hrs Protection against H2O2-induced damage in HUVEC preincubated for 0.5 hrs followed by H2O2 addition and measured after 12 hrs	[PMID: 29432947]
K562	IC₅₀	5.09 μM Compound: 2	Antiproliferative activity against human K562 cells after 72 hrs in presence of piperlongumine by MTT assay Antiproliferative activity against human K562 cells after 72 hrs in presence of piperlongumine by MTT assay	[PMID: 29424539]
MCF7	IC₅₀	>20 μM Compound: Ligustrazine	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29432947]
MCF7	IC₅₀	29.85 μM Compound: TMP	Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
MDA-MB-231	IC₅₀	20.44 μM Compound: TMP	Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
MDA-MB-231	IC₅₀	4.86 μM Compound: Lig	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay	[PMID: 37499289]
MG-63	IC₅₀	10.3 μg/mL Compound: 46	Cytotoxicity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37300915]
NCI-H1975	IC₅₀	5.61 μM Compound: Lig	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay	[PMID: 37499289]
PC-12	EC₅₀	60 μM Compound: Ligustrazine	Neuroprotection against CoCl2-induced toxicity in rat PC12 cells Neuroprotection against CoCl2-induced toxicity in rat PC12 cells	[PMID: 29432947]
PC-12	EC₅₀	64.46 μM Compound: Ligustrazine	Neuroprotection against CoCl2-induced toxicity in rat PC12 cells preincubated for 36 hrs followed by CoCl2 addition measured after 12 hrs by MTT assay Neuroprotection against CoCl2-induced toxicity in rat PC12 cells preincubated for 36 hrs followed by CoCl2 addition measured after 12 hrs by MTT assay	[PMID: 29432947]
Platelet	IC₅₀	265.3 μM Compound: Ligustrazine, TMP	Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry	10.1039/C4MD00022F
SAOS-2	IC₅₀	24.7 μg/mL Compound: 46	Cytotoxicity against human SAOS-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SAOS-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37300915]
SH-SY5Y	EC₅₀	17.59 μM Compound: TMP	Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay	[PMID: 31541868]
SK-HEP1	IC₅₀	9.67 μM Compound: Lig	Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of celastrol by MTT assay	[PMID: 37499289]
U2OS	IC₅₀	54.7 μg/mL Compound: 46	Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37300915]
U-87MG ATCC	IC₅₀	16.15 μM Compound: 2	Antiproliferative activity against human U87MG cells after 72 hrs in presence of piperlongumine by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs in presence of piperlongumine by MTT assay	[PMID: 29424539]

In Vitro

Ligustrazine (1-100 μM) dose-dependently increases NO production in OGD-treated human amniotic epithelial cells by activating the PI3K/Akt pathway, with no significant effect on NO production in normal HAECs^[2].
Ligustrazine (0.1-10 μM) dose-dependently increases p-Akt/Akt and p-eNOS/eNOS in OGD-treated human amniotic epithelial cells by activating the PI3K/Akt pathway, with no significant effect on these factors in normal HAECs^[2].
Ligustrazine protects endothelial cells against LDL-induced damage in an in vitro cell-based system^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ligustrazine (10-120 mg/kg; intraperitoneal injection; intravenous injection; oral administration) exerts protective effects on rat models of ischemic stroke, significantly improves neurological function, reduces the levels of brain injury markers, regulates inflammatory and oxidative stress pathways, inhibits cell apoptosis, and repairs blood-brain barrier permeability^[1].
Ligustrazine (20 mg/kg; i.p.; 15 min after model establishment) improves neurological function in male C57BL/6 mouse models of ischemic stroke^[1].
Ligustrazine (1-10 mg/kg; i.p.; administered once at 2 h and 12 h post-operation) protects Wistar rats against cerebral ischemia-reperfusion injury in a dose-dependent manner by activating the PI3K/Akt pathway, which increases the levels of p-Akt and p-eNOS, improves neurological function, and alleviates brain tissue damage^[2].
Ligustrazine (20-80 mg/kg; p.o.; 6 weeks) dose-dependently inhibits the progression of atherosclerosis and hepatic lipid accumulation in Sprague-Dawley rats, with the daily oral dose of 80 mg/kg reducing the aortic lesion area by 49.0% compared with the untreated atherosclerotic control group^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar rats^[2]
Dosage:

1 mg/kg; 3 mg/kg; 10 mg/kg
Administration:

i.p.; twice (at 2 hours and 12 hours after operation)
Result:

Increased brain tissue levels of p-Akt (normalized to Akt) in a dose-dependent manner.
Increased brain tissue levels of p-eNOS (normalized to eNOS) in a dose-dependent manner.
Significantly improved neurological deficits compared to I/R-only rats.
Dose-dependently alleviated brain cell shrinkage, nuclear deep staining, edema, and necrosis induced by I/R injury.
Had its protective effects reversed by pre-treatment with the PI3K inhibitor wortmannin.

Animal Model:

Sprague-Dawley (male, SPF grade, ~200 g at study start, induced via vitamin D3 injection and atherogenic diet)^[3]
Dosage:

20 mg/kg; 80 mg/kg
Administration:

p.o.; daily; 6 weeks
Result:

Decreased total cholesterol by 65.2%, triglycerides by 53.2%, LDL by 71.2%, and slightly increased HDL at 20 mg/kg dose.
Decreased total cholesterol by 76.7%, triglycerides by 77.9%, LDL by 79.0%, and slightly increased HDL at 80 mg/kg dose.
Decreased circulating endothelial cells by 42.2% at 20 mg/kg dose.
Decreased circulating endothelial cells by 60.0% at 80 mg/kg dose.
Decreased ALT by 13.0% and AST by 10.7% at 20 mg/kg dose.
Decreased ALT by 49.7% and AST by 14.3% at 80 mg/kg dose.
Restored total antioxidant capacity and SOD1 activity at both doses.
Decreased MDA generation by 12.8% at 20 mg/kg dose.
Decreased MDA generation by 23.8% at 80 mg/kg dose.
Reduced thoracic aorta lesion area by 18.9% relative to atherosclerotic controls at 20 mg/kg dose.
Reduced thoracic aorta lesion area by 49.0% relative to atherosclerotic controls at 80 mg/kg dose.
Reduced hepatic lipid accumulation, reversed elevated hepatic TG and LDL levels, and restored reduced hepatic HDL levels at both doses.
Dose-dependently inhibited the induction of antioxidant genes (pgc-1α, sod1, catalase, gpx-1) in the aorta and liver, and suppressed mRNA expression of hepatic fatty acid oxidation genes (pgc-1α, pparα, cpt1a) at both doses.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1124-11-4
Appearance Solid
Masse moléculaire 136.20
Formule C₈H₁₂N₂
Color White to off-white
SMILES

CC1=C(C)N=C(C)C(C)=N1
Synonyms

Chuanxiongzine; Tetramethylpyrazine
Structure Classification
- Others
Initial Source
- Plants
- Umbelliferae
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (11)

All Histological Imaging/StainingIn Vivo ImagingELISAIn Vivo Efficacy StudyCell Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Antioxidants (Basel)

Dopamine D2 Receptor Activation Blocks GluA2/ROS Positive Feedback Loop to Alienate Chronic-Migraine-Associated Pain Sensitization. [Abstract]

2024 Jun 14;13(6):725. PMID: 38929165
Biochem Pharmacol

Tetramethylpyrazine ameliorates sepsis-induced liver injury via inhibiting ferroptosis. [Abstract]

2025 Nov:241:117193. PMID: 40721008

Ligustrazine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Nov:241:117193. [Abstract]

Ligustrazine (TMP, 25-100 mg/kg; i.p.; once daily for 7 days) can ameliorate liver injury in septic mice: Pathological changes in liver tissues of mice in each group, yellow arrows: hepatic cords; black arrows: hepatocytes. H&E staining results showed that in the Sham group, the liver tissues were structurally intact and morphologically normal, with no cell necrosis; in the CLP group, hepatocytes were swollen and necrotic, and hepatic cords were disorganized, accompanied by extensive inflammatory cell infiltration; compared with the CLP group, liver tissue damage in the CLP + XBJ, CLP + TMP L (25 mg/kg), CLP + TMP M (50 mg/kg), and CLP + TMP H (100 mg/kg) groups was significantly improved, hepatic cord structure was restored, and inflammatory cell infiltration was reduced, with the most significant improvement in the CLP + XBJ and CLP + TMP H groups.

Ligustrazine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Nov:241:117193. [Abstract]

Effects of Ligustrazine (TMP, 25-100 mg/kg; i.p.; once daily for 7 days) on serum levels of IL-6, TNF-α, and IL-10 in septic mice.
Eur J Pharmacol

Tetramethylpyrazine ameliorates 5-fluorouracil-Induced cardiotoxicity by inhibiting PANoptosis and suppressing the p38 MAPK/JNK/ERK signaling pathway. [Abstract]

2025 Sep 17:178180. PMID: 40973012

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Representative M-mode echocardiograms. Echocardiographic analysis revealed that Ligustrazine (TMP, 60 mg/kg; i.p.; once daily for 10 days) treatment significantly improved 5-FU (20 mg/kg; i.p.; once daily for 10 days)-induced cardiac dysfunction in BALB/c mice.

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Morphological analysis showed that Ligustrazine (TMP, 60 mg/kg; i.p.; once daily for 10 days) attenuated 5-FU (20 mg/kg; i.p.; once daily for 10 days)-induced reductions in heart size, and significantly restored HW/TL ratio in BALB/c mice.

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Representative images of cardiac tissue with HE staining. Images were taken at 40 × and 400 ×. HE staining revealed that Ligustrazine (TMP, 60 mg/kg; i.p.; once daily for 10 days) significantly ameliorated 5-FU (20 mg/kg; i.p.; once daily for 10 days)-induced cardiomyocyte disarray, inflammatory cell infiltration, and histological disruptions in BALB/c mice.

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Representative micrographs were taken at 100 × magnification with a scale bar of 100 μm. Ligustrazine (TMP, 12.5 μM; 48 h) treatment significantly reversed the reduction in cell density induced by 5-FU (10 μM; 48 h).

Ligustrazine purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 17:178180. [Abstract]

Ligustrazine (TMP) (6.25-100 μM; 48 h) alone exhibited no cytotoxic effects on H9C2 cells. Co-treatment with TMP (12.5–50 μM; 48 h) significantly reversed the suppression of cell viability induced by 10 μM 5-FU.
Cell Signal

Tetramethylpyrazine protects against myocardial ischemia/reperfusion injury via regulating Myl2-mediated NLRP3 signaling pathway inhibition. [Abstract]

2025 Nov:135:112045. PMID: 40754120
Regen Ther

Therapeutic effects of Tetramethylpyrazine on Cartilage in Rat Model of Post-traumatic Osteoarthritis. [Abstract]

2026 Mar 7:32:101098. PMID: 41852452
Exp Cell Res

Tetramethylpyrazine inhibits neutrophil extracellular traps formation and alleviates hepatic ischemia/reperfusion injury in rat liver transplantation. [Abstract]

2021 Sep 1;406(1):112719. PMID: 34273405
Chem Biol Drug Des

Tetramethylpyrazine Targets HDAC6-Mediated PINK1 Degradation to Alleviate Chronic Intermittent Hypoxia-Induced Injury in Human Bronchial Epithelial Cells (16HBE). [Abstract]

2026 Jan;107(1):e70236. PMID: 41549472
Clin Exp Pharmacol Physiol

Ligustrazine and liguzinediol protect against doxorubicin-induced cardiomyocytes injury by inhibiting mitochondrial apoptosis and autophagy. [Abstract]

2023 Nov;50(11):867-877. PMID: 37574718
Vascular

Ligustrazine activate the PPAR-γ pathway and play a protective role in vascular calcification. [Abstract]

2022 Dec;30(6):1224-1231. PMID: 34670463
Research Square Print

November 8th, 2022
Research Square Print

October 11th, 2022.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (367.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

7.3421 mL

36.7107 mL

73.4214 mL

5 mM

1.4684 mL

7.3421 mL

14.6843 mL

10 mM

0.7342 mL

3.6711 mL

7.3421 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (18.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (18.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (18.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/0.5% Tween-80 in Saline water

Solubility: 15.92 mg/mL (116.89 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (283 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Wang Z, et al. The protective effects of ligustrazine on ischemic stroke: a systematic review and meta-analysis of preclinical evidence and possible mechanisms. Front Pharmacol. 2024;15:1373663. Published 2024 Mar 13. [Content Brief]

[2]. Ding Y, et al. The protective effect of ligustrazine on rats with cerebral ischemia-reperfusion injury via activating PI3K/Akt pathway. Hum Exp Toxicol. 2019;38(10):1168-1177. [Content Brief]

[3]. Jiang F, et al. Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress. Pharm Biol. 2011;49(8):856-863. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	7.3421 mL	36.7107 mL	73.4214 mL	183.5536 mL
	5 mM	1.4684 mL	7.3421 mL	14.6843 mL	36.7107 mL
	10 mM	0.7342 mL	3.6711 mL	7.3421 mL	18.3554 mL
	15 mM	0.4895 mL	2.4474 mL	4.8948 mL	12.2369 mL
	20 mM	0.3671 mL	1.8355 mL	3.6711 mL	9.1777 mL
	25 mM	0.2937 mL	1.4684 mL	2.9369 mL	7.3421 mL
	30 mM	0.2447 mL	1.2237 mL	2.4474 mL	6.1185 mL
	40 mM	0.1836 mL	0.9178 mL	1.8355 mL	4.5888 mL
	50 mM	0.1468 mL	0.7342 mL	1.4684 mL	3.6711 mL
	60 mM	0.1224 mL	0.6118 mL	1.2237 mL	3.0592 mL
	80 mM	0.0918 mL	0.4589 mL	0.9178 mL	2.2944 mL
	100 mM	0.0734 mL	0.3671 mL	0.7342 mL	1.8355 mL

Bioz

Ligustrazine

11 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ligustrazine

Dimethyl sulfoxide, meets analytical specification of Ch.P.

Ferulic acid

Paeoniflorin

Kaempferol

(Z)-Ligustilide

Tween 80

Astragaloside IV

Evodiamine

Angiotensin II human

Apigenin

Baicalein

D-Glucose

Publications Citing Use of MedChemExpress (MCE) Ligustrazine

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform NO Synthase

Voir tous les produits spécifiques à Isoform Aminotransferases (Transaminases)

Activité biologique

Chemical Information

Publications (11)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Ligustrazine

Dimethyl sulfoxide, meets analytical specification of Ch.P.

Ferulic acid

Paeoniflorin

Kaempferol

(Z)-Ligustilide

Tween 80

Astragaloside IV

Evodiamine

Angiotensin II human

Apigenin

Baicalein

D-Glucose

Publications Citing Use of MedChemExpress (MCE) Ligustrazine

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform NO Synthase

Voir tous les produits spécifiques à Isoform Aminotransferases (Transaminases)

Activité biologique

Chemical Information

Publications (11)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Ligustrazine Related Classifications

HY-N0264 Related Classifications

Bioz